Docetaxel Export Market Intelligence: India's 253 Suppliers Shipping to 120 Countries — TransData Nexus 2026

Q: Who are the top docetaxel exporters from India?

The top docetaxel exporters from India are: 1. FRESENIUS KABI ONCOLOGY LIMITED — $8.4M (21.1% market share); 2. MYLAN LABORATORIES LIMITED — $7.0M (17.7% market share); 3. KWALITY PHARMACEUTICALS LIMITED — $4.1M (10.3% market share); 4. INTAS PHARMACEUTICALS LIMITED — $3.2M (8.0% market share); 5. JODAS EXPOIM PRIVATE LIMITED — $2.6M (6.5% market share). Together they account for 63.7% of India's total docetaxel export value.

Q: What is the total export value of docetaxel from India?

The total export value of docetaxel from India is $39.6M USD, recorded across 2,634 shipment transactions from 253 active exporters to 120 destination countries. The average shipment value is $15.0K.

Q: Which countries import docetaxel from India?

India exports docetaxel to 120 countries worldwide. The top importing countries are: UNITED STATES (26.6% share, $10.5M), AFGHANISTAN (10.1% share, $4.0M), RUSSIA (6.7% share, $2.7M), GERMANY (6.4% share, $2.5M), PHILIPPINES (5.9% share, $2.3M). These five markets account for 55.7% of total export value.

Q: What is the HS code for docetaxel exports from India?

The primary HS code for docetaxel exports from India is 30049044. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of docetaxel exports from India?

The average unit price for docetaxel exports from India is $61.31 USD per unit, with prices ranging from $0.01 to $49422.63 depending on formulation, packaging, and order volume. The total market is valued at $39.6M across 2,634 shipments.

Q: Which ports handle docetaxel exports from India?

The primary ports for docetaxel exports from India are DELHI AIR CARGO ACC (INDEL4) (20.1% of shipments), DELHI AIR (15.8% of shipments), SAHAR AIR CARGO ACC (INBOM4) (14.4% of shipments), SAHAR AIR (14.1% of shipments), Bombay Air (5.0% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of docetaxel?

India is one of the world's leading exporters of docetaxel due to its large base of 253 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports docetaxel to 120 countries, demonstrating 62% global market coverage.

Q: What certifications do Indian docetaxel exporters need?

Indian docetaxel exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import docetaxel from India?

There are 641 registered buyers importing docetaxel from India, spread across 120 countries. The repeat buyer rate is 61.9%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top docetaxel supplier from India?

FRESENIUS KABI ONCOLOGY LIMITED is the leading docetaxel exporter from India with a market share of 21.1% and total export value of $8.4M across 356 shipments. The top 5 suppliers together control 63.7% of total export value.

Suresh Sormare

Docetaxel

India Pharmaceutical Trade Intelligence

$39.6M253 Suppliers120 CountriesHS 30049044

ExportsIndia → UNITED STATES26.6%India → AFGHANISTAN10.1%

ImportsGERMANY → India$266.0K SINGAPORE → India$165.7K

#1 Supplier: FRESENIUS KABI #1 Buyer: MYLAN INSTITUTIONAL

Docetaxel Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Docetaxel to the World

Between 2022 and 2026, India exported $39.6M worth of docetaxel across 2,634 verified shipments to 120 countries — covering 62% of world markets in the Oncology segment. The largest destination is UNITED STATES (26.6%). FRESENIUS KABI ONCOLOGY LIMITED leads with a 21.1% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·HS 30049044

Docetaxel export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Docetaxel export data snapshot — $39.6M · 253 exporters · 120 countriesTransData Nexus · Indian Customs Data

Top Docetaxel Exporters from India

253 active exporters · Ranked by export value

View all 253 →

Top Docetaxel Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	FRESENIUS KABI ONCOLOGY LIMITED	$8.4M	356	21	21.1%
2	MYLAN LABORATORIES LIMITED

Top Countries Importing Docetaxel from India

120 destination markets · Ranked by import value

All 120 countries →

Top Countries Importing Docetaxel from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$10.5M	26.6%
2	AFGHANISTAN	$4.0M	10.1%
3	RUSSIA	$2.7M	6.7%
4	GERMANY	$2.5M	6.4%
5	PHILIPPINES	$2.3M	5.9%
6	MEXICO	$1.7M	4.4%
7	COLOMBIA	$1.4M	3.5%
8	THAILAND	$1.1M	2.9%
9	CHILE	$1.1M	2.7%
10	MALTA	$1.0M	2.5%

UNITED STATES is India's largest docetaxel export destination, absorbing 26.6% of total exports worth $10.5M. The top 5 importing countries — UNITED STATES, AFGHANISTAN, RUSSIA, GERMANY, PHILIPPINES — together account for 55.7% of India's total docetaxel export value. The remaining 115 destination countries collectively receive the other 44.3%, indicating a well-diversified global distribution network spanning all major continents.

Who Supplies Docetaxel to India?

9 origin countries · Total import value: $547.7K

India imports docetaxel from 9 countries with a combined import value of $547.7K. The largest supplier is GERMANY ($266.0K, 16 shipments), followed by SINGAPORE and UNITED STATES. All values are from Indian Customs (DGFT) import records.

Countries Supplying Docetaxel to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	GERMANY	$266.0K	16	48.6%
2	SINGAPORE	$165.7K	4	30.3%
3	UNITED STATES	$65.3K	2	11.9%
4	CHINA	$26.7K	2	4.9%
5	BRAZIL	$16.7K	4	3.1%
6	BULGARIA	$7.0K	2	1.3%
7	THAILAND	$90	4	0.0%
8	SWITZERLAND	$60	1	0.0%
9	MALTA	$26	2	0.0%

GERMANY is the largest supplier of docetaxel to India, accounting for 48.6% of total import value. The top 5 origin countries — GERMANY, SINGAPORE, UNITED STATES, CHINA, BRAZIL — together supply 98.7% of India's docetaxel imports. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Docetaxel

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, docetaxel is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The regulatory pathway for docetaxel involves demonstrating bioequivalence to the reference listed drug, Taxotere. As of March 2026, there are no active FDA import alerts specifically targeting docetaxel, indicating compliance with FDA standards among Indian exporters. Given that 26.6% of India's docetaxel exports are destined for the U.S., the absence of import alerts underscores the adherence of Indian manufacturers to stringent FDA regulations.

2EU & UK Regulatory Framework

In the European Union, docetaxel is authorized for marketing by the European Medicines Agency (EMA). The reference medicine, Taxotere, received EU-wide marketing authorization on 27 November 1995. Generic versions, such as Docetaxel Accord, were subsequently approved, with Docetaxel Accord receiving marketing authorization on 22 May 2012. However, some generic authorizations have been withdrawn; for instance, Docetaxel Zentiva's authorization was withdrawn on 25 April 2022 at the request of the marketing authorization holder for commercial reasons. Manufacturers exporting to the EU and UK must comply with Good Manufacturing Practice (GMP) requirements as stipulated by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA).

3WHO Essential Medicines & Global Standards

Docetaxel is included in the World Health Organization's Model List of Essential Medicines, highlighting its significance in cancer treatment. The drug is also subject to international pharmacopoeia standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

4India Regulatory Classification

In India, docetaxel is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing under the Drug Price Control Order (DPCO). As of March 2026, the ceiling price for docetaxel formulations is set by the NPPA to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

5Patent & Exclusivity Status

The primary patents for docetaxel have expired, leading to the availability of multiple generic versions in the global market. This has intensified competition among manufacturers, including the 253 active Indian exporters, and has contributed to the average Free on Board (FOB) unit price of $61.31.

6Recent Industry Developments

In June 2025, the NPPA revised the ceiling price for docetaxel formulations, reducing it by 5% to enhance affordability for patients. In September 2025, the CDSCO issued new guidelines for the export of oncology drugs, including docetaxel, emphasizing stringent quality control measures. In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of docetaxel for cancer treatment. In February 2026, the EMA approved a new generic version of docetaxel, expanding treatment options within the EU. In March 2026, the FDA conducted inspections of Indian manufacturing facilities producing docetaxel, resulting in compliance certifications for several exporters.

These developments reflect the dynamic regulatory landscape for docetaxel, underscoring the importance of continuous compliance with international standards to maintain market access and competitiveness.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Supply Chain Risk Assessment — Docetaxel

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Docetaxel, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of KSMs used in Indian pharmaceutical manufacturing are sourced from China, creating a significant dependency. This reliance exposes the supply chain to vulnerabilities stemming from geopolitical tensions, trade disputes, and regulatory changes in China.

In response to this dependency, the Indian government has initiated measures to bolster domestic production of critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under the Production Linked Incentive (PLI) scheme, aiming to manufacture essential molecules like Penicillin G and Clavulanic Acid, which had not been produced domestically for over two decades. These efforts are projected to reduce India's import dependence on key pharma ingredients by half.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data indicates that the top five exporters account for 63.7% of Docetaxel exports from India, with FRESENIUS KABI ONCOLOGY LIMITED leading at a 21.1% share. This high supplier concentration poses a risk, as disruptions affecting these key exporters could significantly impact global supply.

The PLI scheme, launched in 2020, aims to incentivize domestic production of APIs and KSMs to reduce reliance on imports. While progress has been made, the full impact on diversifying the supplier base for Docetaxel remains to be seen.

Access Complete Docetaxel Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 2,634 transactions across 120 markets.

Request Demo View Pricing

Frequently Asked Questions — Docetaxel Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top docetaxel exporters from India?

The leading docetaxel exporters from India are FRESENIUS KABI ONCOLOGY LIMITED, MYLAN LABORATORIES LIMITED, KWALITY PHARMACEUTICALS LIMITED, and 12 others. FRESENIUS KABI ONCOLOGY LIMITED leads with 21.1% market share ($8.4M). The top 5 suppliers together control 63.7% of total export value.

What is the total export value of docetaxel from India?

The total export value of docetaxel from India is $39.6M, recorded across 2,634 shipments from 253 active exporters to 120 countries. The average shipment value is $15.0K.

Which countries import docetaxel from India?

India exports docetaxel to 120 countries. The top importing countries are UNITED STATES (26.6%), AFGHANISTAN (10.1%), RUSSIA (6.7%), GERMANY (6.4%), PHILIPPINES (5.9%), which together account for 55.7% of total export value.

What is the HS code for docetaxel exports from India?

The primary HS code for docetaxel exports from India is 30049044. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Docetaxel

Docetaxel

How India Exports Docetaxel to the World

Top Docetaxel Exporters from India

Top Countries Importing Docetaxel from India

Who Supplies Docetaxel to India?

Quick Facts

Related Oncology

Related Analysis

Need Details?

Regulatory Landscape — Docetaxel

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Supply Chain Risk Assessment — Docetaxel

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Docetaxel Trade Intelligence

Frequently Asked Questions — Docetaxel Exports from India

Who are the top docetaxel exporters from India?

What is the total export value of docetaxel from India?

Which countries import docetaxel from India?

What is the HS code for docetaxel exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of docetaxel exports from India?

Which ports handle docetaxel exports from India?

Why is India a leading exporter of docetaxel?

What certifications do Indian docetaxel exporters need?

How many buyers import docetaxel from India?

What is the market share of the top docetaxel exporter from India?

Analysis Methodology